Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Levodopa

Known as: beta-(3,4-Dihydroxyphenyl)-L-alanine, 3,4-Dihydroxy-L-phenylalanine, .beta.-(3,4-Dihydroxyphenyl)-L-alanine 
An amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and… Expand
National Institutes of Health

Related topics

Related topics

37 relations

Narrower (19)

2,4,5-trihydroxyphenylalanine quinone2,4-dihydroxyphenylalanine3,4,6-trihydroxyphenylalanine quinone3-O-methyl-6-fluoro-dopa
Expand

Broader (2)

Antiparkinson AgentsDopa
Carbidopa 10 MG / Levodopa 100 MG Disintegrating Oral TabletCarbidopa 10 MG / Levodopa 100 MG Oral TabletCarbidopa 10 MG / Levodopa 100 MG Oral Tablet [Sinemet]Carbidopa 25 MG / Levodopa 100 MG Disintegrating Oral Tablet
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Parkinson disease (PD) treatment options have conventionally focused on dopamine replacement and provision of symptomatic relief… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Review
2018
Review
2018
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of… Expand
Review
2018
Review
2018
Fatigue in Parkinson's disease: A systematic review and meta‐analysis
We conducted a systematic review and meta‐analysis aimed at establishing robust prevalence estimates and identifying clinical… Expand
Review
2018
Review
2018
Human tyrosine hydroxylase in Parkinson’s disease and in related disorders
Parkinson’s disease (PD) is an aging-related movement disorder mainly caused by a deficiency of neurotransmitter dopamine (DA) in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2018
Review
2018
Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review
To systematically review evidence for pharmacological/neurosurgical interventions for managing dystonia in individuals with… Expand
Review
2018
Review
2018
Parkinson's disease: A review
Parkinson's disease is a common movement disorder seen in neurological practice, but the diagnosis and management is challenging… Expand
Review
2018
Review
2018
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease
The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar’s outstanding discovery of the selective… Expand
  • figure 1
  • figure 2
Review
2017
Review
2017
Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases
Objectives Dopamine dysregulation syndrome (DDS) is an uncommon complication of the treatment of Parkinson’s disease… Expand
Review
2017
Review
2017
Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease
Importance Evidence suggests that development of autonomic dysfunction (AutD) may negatively affect disease course and survival… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Review
2017
Review
2017
Respiratory dysfunction in Parkinson's disease.
Respiratory dysfunction has been associated with Parkinson's disease since it was first described in 1817. The respiratory… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE